Is Wall Street Bullish or Bearish on ResMed Stock?
/Resmed%20Inc_%20HQ%20photo-by%20JHVEPhoto%20via%20iStock.jpg)
ResMed Inc. (RMD), headquartered in San Diego, California, manufactures, distributes, and markets medical devices and cloud-based software applications. Valued at $43 billion by market cap, the company offers a range of products for respiratory disorders, including diagnostic tools like ApneaLink Air and NightOwl, cloud-based platforms like AirView and myAir for patient monitoring, and U-Sleep for HME providers, connectivity solutions, as well as out-of-hospital software solutions.
Shares of this sleep tech giant have outperformed the broader market over the past year. RMD has gained 26.1% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 14.3%. In 2025, RMD stock is up 25%, surpassing SPX’s 9.5% rise on a YTD basis.
Zooming in further, RMD’s outperformance is also apparent compared to iShares U.S. Medical Devices ETF (IHI). The exchange-traded fund has gained about 6.6% over the past year. Moreover, RMD’s double-digit returns on a YTD basis outshine the ETF’s 6.3% gains over the same time frame.
On Jul. 31, RMD shares closed down by 2% after reporting its Q4 results. Its adjusted EPS of $2.55 exceeded Wall Street expectations of $2.46. The company’s revenue was $1.35 billion, exceeding Wall Street forecasts of $1.32 billion.
For fiscal 2026, ending in June 2026, analysts expect RMD’s EPS to grow 13.7% to $10.86 on a diluted basis. The company’s earnings surprise history is impressive. It beat the consensus estimate in each of the last four quarters.
Among the 18 analysts covering RMD stock, the consensus is a “Moderate Buy.” That’s based on nine “Strong Buy” ratings, two “Moderate Buys,” six “Holds,” and one “Strong Sell.”
This configuration is more bullish than two months ago, with one analyst suggesting a “Moderate Buy.”
On Aug. 1,RBC Capital kept an “Outperform” rating on RMD and raised the price target to $300, implying a potential upside of 5% from current levels.
The mean price target of $289.25 represents a 1.2% premium to RMD’s current price levels. The Street-high price target of $325 suggests an upside potential of 13.7%.
On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.